ConSynance

News

July 18th, 2018, ConSynance’s CSTI-300 Irritable Bowel Syndrome Data Presented at International Scientific Meeting

ConSynance’s CSTI-300 data was presented showing its’ potential as an efficacious and well tolerated drug candidate for the treatment of IBS-D. Please see: https://www.businesswire.com/news/home/20180718005436/en/ConSynance%E2%80%99s-CSTI-300-Irritable-Bowel-Syndrome-Data-Presented


May 29th, 2018, ConSynance Initiates Toxicology Studies on CSTI-300 for Irritable Bowel Syndrome.

ConSynance Initiates Toxicology Studies on CSTI-300 for Irritable Bowel Syndrome. Please see our press release: https://www.businesswire.com/news/home/20180529005680/en/ConSynance-Initiates-Toxicology-Studies-CSTI-300-Irritable-Bowel


May 25th, 2018, ConSynance attending 2018 BIO International Convention in Boston.

We are attending 2018 BIO International Convention in Boston, June 4-7.


April 25th, 2018, ConSynance presents NASH results

Our CEO Dr. Peter Guzzo presented data on the company's Phase I nonalcoholic steatohepatitis (NASH) drug candidate, CSTI-100, at NASH Summit 2018, on April 24 in Boston. Please see: https://www.businesswire.com/news/home/20180425005097/en/ConSynance-Presents-NASH-Results


February 5th, 2018, CEO Dr. Peter Guzzo attending BIO CEO & Investor Conference in NYC Feb 12-13.

Our CEO Dr. Peter Guzzo is attending BIO CEO & Investor Conference in NYC Feb 12-13. The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.


August 27th, 2017, Dr. Nicholas Barnes presented our 5-HT3 receptor partial agonist CSTI-300 at NeuroGASTRO 2017.

Dr. Nicholas Barnes, our advisor, presented a poster titled "Tickling the 5-HT3 receptor; potential therapeutic opportunities for patients with diarrhea-predominant irritable bowel syndrome from the selective 5-HT3 receptor partial agonist, CSTI-300", at NeuroGASTRO 2017, held in Cork, Ireland, August 24th to 26th. NeuroGASTRO is a well-established European event that brings together leading experts and emerging young investigators actively involved in neurogastroenterology, digestive motility and functional gastrointestinal diseases from Europe and from all around the world to discuss cutting-edge research. For a copy of the poster, click here.


July 1st, 2016. Our new location!

We have officially moved into our new office located within the Biotech Business Incubator at the East Campus of State University of New York. Our new address is 11 University Place, Rensselaer, NY 12144.


May 1st, 2016. ConSynance Therapeutics, Inc. and pharmacologist Nicholas Barnes, Ph.D. join forces to advance novel 5-HT3 receptor modulators for Irritable Bowel Syndrome.

ConSynance Therapeutics, Inc. and Nicholas Barnes, Ph.D. have entered into a research agreement to develop a new therapy for Irritable Bowel Syndrome (IBS) by pursuing a pharmacological strategy that targets the 5-HT3 receptor by a different mechanism. "I have known and worked with Nick for over 10 years on various projects, including this 5-HT3 project when it was started at Albany Molecular Research," commented Peter Guzzo, Ph.D., Co-founder and VP of R&D at ConSynance; "he has tremendous knowledge of the area and I am very excited to work with him again on this project". IBS is a highly prevalent gastrointestinal disorder for which there is currently no effective treatment widely available. ConSynance has an exclusive license to a series of novel 5-HT3 receptor modulators with desirable pharmaceutical properties that targets the receptor by a different mechanism predicted to deliver clinical efficacy coupled with a more acceptable side-effect profile than current standard of care. The goal of the collaboration is to further develop a 5-HT3 receptor modulator as a best-in-class treatment for IBS and attract a pharma partner to help progress to market. Dr. Barnes has extensive expertise with the pharmacology of the neurotransmitter serotonin (5-HT), particularly with the 5-HT3 receptor, and is the Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is the principal founder and CEO of Celentyx Ltd, a venture capital financed pharmaceutical R&D company focusing on diseases of the immune system, and has a proven track record in the investigation of drug targets and the delivery of development compounds. He is also a Fellow of the British Pharmacological Society and an Honorary Professor at a number of major universities around the globe as well as being Editor-in-Chief, Editor and Associate Editor for the international journals Frontiers in Neuropharmacology, Neuropharmacology, and Frontiers in Neuroscience, respectively.

For further information on the 5-HT3 receptor project, see link here


April 6th, 2016. Dr. Peter Guzzo co-authored a review on Inhibitors of Glycine Transporter-1

A review entitled “Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders” co-authored by Dr. Peter Guzzo, Co-founder and VP of R&D was recently published on Current Topics in Medicinal Chemistry, Volume 16. This review examines the pharmacological aspects of GlyT-1 inhibition and describes drug discovery and development efforts toward the identification of novel inhibitors. The PubMed link to the article is here.


Oct 28, 2015 CSTI entered research collaboration with Dr. Kokkotou of Harvard Medical School/BIDMC

ConSynance Therapeutics, Inc. (CSTI) and Efi Kokkotou, M.D., Ph.D., Associate Professor of Medicine at Harvard Medical School and Principal Investigator at Beth Israel Deaconess Medical Center, have entered into a research collaboration to study the effects of CSTI-100 (ALB-127158) in various models of inflammatory bowel disease. CSTI-100 is an orally acting melanin-concentrating hormone receptor 1 (MCHR1) antagonist that has demonstrated good safety, tolerability and low central nervous system exposure in phase I studies. Research from Dr. Kokkotou’s lab has established the role of MCHR1 in chronic intestinal inflammation. The collaborative research will reveal the potential of CSTI-100 as a treatment for inflammatory bowel disease through a novel mechanism of action. It will also take advantage of a human sample-based drug screening platform recently developed in Dr. Kokkotou’s lab to identify patients with inflammatory bowel disease more likely to benefit from the new treatment.

For further information on CSTI-100, see link here